Flow Diagram.

<p>Footnote: * To be included in this meta-analysis, studies had to be (i) randomized trials of fibrates, (ii) placebo-controlled, and (iii) have a mean (or median) duration of patient follow-up of at least 2 years.</p

Fibrate use and cancer risk: Meta-analysis and subgroup analysis.

<p>RR, risk ratio; CI, confidence interval; d.f., degrees of freedom.</p

Forest plot of the meta-analysis of fibrate use and cancer incidence.

<p>Footnote: The risk ratios and their 95% confidence intervals are displayed on a logarithmic scale. The size of the data markers represents the relative weight of the trial according to size and occurrence of the outcome being measured.</p

Meta-regression’s results.

<p>RR, risk ratio; CI, confidence interval.</p><p>Results are exponentiated regression coefficients and their 95% CIs, which show the proportional change in risk ratio for every one scale increase.</p

Incidence of and/or deaths from cancer in the randomized placebo-controlled trials of fibrates.

*<p>Crude rates;</p>**<p>Reported in Saha et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0045259#pone.0045259-Saha1" target="_blank">[43]</a>.</p><p>Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; BECAIT, Bezafibrate Coronary Atherosclerosis Intervention Trial; BIP, Bezafibrate Infarction Prevention; CDP, Coronary Drug Project; DAIS, Diabetes Atherosclerosis Intervention Study; DIS, Diabetes Intervention Study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; HHS, Helsinki Heart Study; LEADER, Lower Extremity Arterial Disease Event Reduction; LOCAT, Lopid Coronary Angiography Trial; SENDCAP, St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention; VA HIT, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial; WHO, World Health Organization; RR, relative risk (risk ratio); CI, confidence interval.</p

Fibrate use and cancer deaths: Subgroup analyses.

<p>Fibrate use and cancer deaths: Subgroup analyses.</p

Fibrate use and cancer incidence: Subgroup analyses.

<p>Fibrate use and cancer incidence: Subgroup analyses.</p

Characteristics of notified TB cases.

<p>Abbreviations: LTBI – Latent Tuberculosis Infection, NTM – Non-tuberculous Mycobacteria, HCDCP – Hellenic Centre for Disease Control and Prevention, TB – Tuberculosis, PHD – Prefectural Public Health Department.</p

Forest plot of the meta-analysis of fibrate use and cancer deaths.

<p>Footnote: The risk ratios and their 95% confidence intervals are displayed on a logarithmic scale. The size of the data markers represents the relative weight of the trial according to size and occurrence of the outcome being measured.</p

Characteristics of studies included in the meta-analysis.

<p>Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; BECAIT, Bezafibrate Coronary Atherosclerosis Intervention Trial; BIP, Bezafibrate Infarction Prevention; CDP, Coronary Drug Project; DAIS, Diabetes Atherosclerosis Intervention Study; DIS, Diabetes Intervention Study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; HHS, Helsinki Heart Study; LEADER, Lower Extremity Arterial Disease Event Reduction; LOCAT, Lopid Coronary Angiography Trial; SENDCAP, St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention; VA HIT, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial; WHO, World Health Organization; r, randomized; db, double-blind; pc, placebo-controlled; DM, Diabetes Mellitus; CAD, Coronary Artery Disease; NIDDM, Non-Insulin-Dependent Diabetes Mellitus; LEAD, Lower Extremity Arterial Disease.</p